ClinicalTrials.Veeva

Menu
B

Bay Area Retina Associates | Walnut Creek, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
Bevacizumab
RBM-007
RO7200220
Triamcinolone Acetonide
Vamikibart
dexamethasone
Lampalizumab
APL-2
-Ranibizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 47 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, toler...

Active, not recruiting
Diabetic Macular Edema
Drug: Vamikibart
Drug: Ranibizumab

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Other: Sham Procedure

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Enrolling
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), in...

Invitation-only
Neovascular (Wet) AMD
Drug: ABI-110 High Dose
Drug: ABI-110 Low Dose

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular de...

Active, not recruiting
Age-Related Macular Degeneration
Nonexudative Age-related Macular Degeneration
Device: i-Lumen(TM) AMD
Device: i-Lumen(TM) AMD Sham

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling
Age Related Macular Degeneration (ARMD)
Drug: Elamipretide
Drug: Placebo

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate th...

Enrolling
Neovascular Age-related Macular Degeneration
Biological: AM712(ASKG712)

Trial sponsors

Jaeb Center for Health Research logo
Roche logo
A
Genentech logo
R
B
Aerie Pharmaceuticals logo
A
Allergan logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems